跳至主要内容
临床试验/NCT07029854
NCT07029854尚未招募不适用

Laser Acupoints Stimulation on Xerostomia Related Chemoradiotherapy for Head and Neck Cancer Patients

Cairo University1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2025年6月18日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
54
试验地点
1
主要终点
Xerostomia Inventory score

研究概览

简要总结

The purpose of the study is to evaluate to effect of LASER acupoints stimulations on xerostomia patients during chemoradiation therapy after head and neck cancer.

详细描述

The current diagnosis is based on the primary complaint reported by the patient. A previous study found that patients with cancer reported different degrees of dry mouth, reduced drinking and eating and waking up at night due to dry mouth and that the risk of progression to oral ulcers was higher among this patient population and could significantly affect the quality of life.

Acupuncture may be effective in treating xerostomia and also, acupuncture has been shown to increase salivary flow in healthy volunteers.

As xerostomia gradually comes to the attention of the wider medical community, clinical evidence is slowly starting to amass to help assess which treatments are most effective, but more research is needed. Furthermore, there is a lack in the quantitative knowledge and information in the published studies about benefits of acupuncture on xerostomia during chemo radiation therapy. So, this study is designed to outline the therapeutic efficacy of acupuncture on xerostomia during chemo radiation therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
40 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Chemoradiation therapy
  • •Carcinoma in the head and neck area (NPC)
  • •Anatomically intact parotid and submandibular glands.
  • •All patients will be clinically and medically stable when attending the study.

排除标准

  • •They had a history of xerostomia;
  • •They had suspected or confirmed physical closure of salivary gland.
  • •ducts on either side.
  • •They had known bleeding disorders.
  • •They Were taking heparin or warfarin.
  • •They had contraindications for the use of acupuncture at any acupoints.
  • •They had history of cerebrovascular accident or spinal cord injury.
  • •They had taken any drug or herbal medicine in the past 30 days that could affect salivary function.
  • •They were planning to, or ended up taking such a substance during the study.
  • •Any therapy that may affect treatment.

研究组 & 干预措施

LASER acupoints therapy + Medical treatment

Experimental

This group will include twenty-seven patients suffering xerostomia (dryness of mouth), who will receive LASER acupoints therapy (3 times per week, for 4 weeks), plus medical treatment.

干预措施: Medical treatment (Other)

LASER acupoints therapy + Medical treatment

Experimental

This group will include twenty-seven patients suffering xerostomia (dryness of mouth), who will receive LASER acupoints therapy (3 times per week, for 4 weeks), plus medical treatment.

干预措施: LASER acupoints therapy (Other)

Pseudo-LASER acupoints therapy + Medical treatment

Placebo Comparator

This group will include twenty-seven patients suffering xerostomia (dryness of mouth), who will receive pseudo-LASER acupoints therapy plus medical treatment (for 4 weeks).

干预措施: Medical treatment (Other)

Pseudo-LASER acupoints therapy + Medical treatment

Placebo Comparator

This group will include twenty-seven patients suffering xerostomia (dryness of mouth), who will receive pseudo-LASER acupoints therapy plus medical treatment (for 4 weeks).

干预措施: Pseudo-LASER acupoints therapy (Other)

结局指标

主要结局

Xerostomia Inventory score

时间窗: 4 weeks

Participants will complete the Xerostomia Inventory (XI) questionnaire, a validated tool measuring the subjective burden of dry mouth. It consists of 11 items covering symptoms such as dryness of the mouth, lips, eyes, nose, and face, difficulty with dry foods, sipping liquids, sucking sweets, and nighttime thirst. Responses are rated on a 5-point Likert scale from Never (1) to Very Often (5). Total scores are converted to a 0-10 scale, where 0 represents no burden and 10 indicates an excruciating burden. The questionnaire will be administered at baseline and post-treatment.

次要结局

  • Stimulated salivary flow rate (SSFR) by Sialometry(4 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nehal Gamal Ebrahim Elwerish

Principal Investigator

Cairo University

研究点 (1)

Loading locations...

相似试验